Remarkably, siRNA knockdown of DLC1 or its genetic ablation in A549 cells abolished most of the growth inhibitory activity of the three-drug combination, as determined by inhibition of anchorage-independent growth or tumor xenografts, although each inhibitor has multiple targets, strongly suggesting that DLC1 is the predominant antitumor target of the drug combination. Here, DLC1 is linked to neoplasm.